Opinion|Videos|January 10, 2025
MRD Outcomes From CEPHEUS at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the role of MRD as a biomarker in multiple myeloma treatment, highlighting its potential to guide therapy decisions and improve patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a brief overview of the CEPHEUS study and the expanded analysis of MRD outcomes presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What additional MRD outcomes were presented?
Advertisement
Related to this article
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, and quality of life.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.
Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.
At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
3
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
4
CHEST: The Face of Lung Cancer Has Changed, but Screening, Care Have Gaps
5